Image provided by: Texas A&M University
About The Battalion. (College Station, Tex.) 1893-current | View Entire Issue (Sept. 10, 2003)
6A TRAVEL ERSY Wednesday, September 10, 2003 EWS THE BATTALI | ,HK HA1 ,ALI ' Welcome Back!...Now GO AWAY Student Class/Discount Airfare Worldwide Expert Travel Advice Eurail, Britrail, Japan Rail passes Budget, Camping, Adventure & Contiki 18-35 Tours International Student/Youth Identity Cards Spring Break Packages...and more! U.N. Security Council delays vote 01 Bea lifting Libya sanctions until Friday 21 staU ° 7 ‘Ithp A/tic ~ , . Aup. 15. when l.ihva ar>reed to a ” ' "* B*'* TRAVEL CUTS See the world your way By Edith Lederer THE ASSOCIATED PRESS Toll Free 1-800-592-CUTS (2887) usareservations@travelcuts.com www.travelcuts.com Welcome Back College Students! Luby’sjHH iimgfSi Daily after 4:15 pm & All Day SATURDAY 10-^ OFF to students with a valid college ID. All You Can Eat SL DESSERTS, DRINKS AND PREMIUM ITEMS ^ ARE EXTRA. LIMITED TIME. DINE-IN ONLY. UNITED NATIONS — The U.N. Security Council delayed a vote to lift sanctions against Libya until Friday, after France threatened a veto to gain greater compensation for the relatives of people killed in a French air line bombing. After difficult closed-door negotiations, the council on Tuesday agreed to give the French a last chance to win a settlement with Libya similar to that for families of victims of the Lockerbie air disaster. But Britain’s U.N. Ambassador Emyr Jones Parry, the current council president, and other members made clear they would not accept any fur ther delays. In a fast-moving day of diplomacy, French Foreign Minister Dominique de Villepin spoke twice with his British counterpart. Jack Straw, threat ening to veto the lifting of sanc tions unless families of the 1989 UTA bombing were satisfied. The French Foreign Ministry said in a statement that “a fair agreement... appears to be with in reach.” But Foreign Ministry spokesman Herve Ladsous said. ‘‘The victims’ families must confirm their satisfaction with the negotiations — that would be the deciding factor for us.” The United States and Britain have pressed for a vote since Aug. 15, when Libya agreed to a $2.7 billion compensation deal for families of the 270 Lockerbie bombing victims and acknowledged responsibility for the attack. The deal will give each vic tim’s family $5 million to $10 million, a settlement that embar rassed France. The French government set tled with Libya in 1999 for just $33 million to be shared by fam ilies of the 170 people killed in the bombing of a UTA flight over Niger in 1989 — giving relatives of each victim about $194,000. When French families learned of the Lockerbie settlement, they demanded more money. The United States had been so sure of a vote to end more than a decade of sanctions stemming from the Lockerbie bombing that 50 relatives of the victims sat in the Security Council’s visitor gallery to witness it. Instead, on a procedural vote, all 15 council members then voted in favor of adjourning the meeting until Friday. “The council is united and detennined to address this issue at 10:30 a.m. on Friday,” Jones Parry said. “I don’t want to talk about any more delay.” U.S. Ambassador John Negroponte said the United States was “very disappointed” that the vote didn’t take place Tuesday “and our hearts go out to the fam ilies of the victims who have been waiting and suffering so patiently U.N. sanctions against Libya Libya has been under sanctions since 1992 in an attempt to fora cooperation with investigations in the 1988 Lockerbie bombing arc the 1989 bombing of a French plane over Niger A vote to lift sanctions was delayed Tuesday due to threat of French veto The sanctions: ® <S> ® <8> ® Forbid aircraft from taking off. landing or flying over Libya unless humanitarian approved; prohibit sale of aircraft equipment •Freeze Libya's assets abroad, excluding revenue from oil, natural gas or agricultural commodities t exports NOTE Measures wers suspended (not lifted; were handed over lor trial. On Aug IS. 2003 demands, paving the way for the counci vot •Ban sale of equipment for oil refineries and transporting oil. excluding oil production equipment Prohibit sale of arms, military vehicles and weapons Limit the number of mtemation* diplomatic staff in advice Libya lUnasdM hen two LocAartss aapea nphed with all cound SOURCES Urated Nations. Associated Pn for the day to come when this vote takes place." France’s U.N. Ambassador Jean-Marc de La Sabliere would not predict what will happen in Friday’s vote. “What the council has decid ed ... was to give a last chance to these negotiations,” he said. The sanctions — a ban on amis sales and air links with Libya — were indefinitely suspended in 1999 after two Libyans sought in the Lockerbie bombing were handed over for trial. But Libya has pressed for the embargoes to be lifted — not just suspended — to restore its standing in the inter national community. Britain and the United States have said Libya has met all the (Congratulations to the 2003 Pledge Class! Chelsea Adams Jacque LaCroix Kelsey Andrews Whitney Bledsoe Holly Bohmfalk Candice Brown ayla Burnett Michelle Cadavid llison Coggins Betsy Collins Ginne Cook Rachel Curry Nicolle Cusumano legan Dickerson laire Dotson Lauren Easterwood arah Ford Christina Fuertes Reagan Green Mallory Grubb Kate Higdon ourtney Hogan aylor Hyde Casey Johnson LauraJones mily Kloppenburg Alix Koetting Kolbi Krus Molly Lancaster, Alicia Lloyd Hillary McDaniel April Moore Lindsay Nallie Raine Neal Kristin Oberfeld Kati Peninger Jenn Pfeil Hilary Phillips Ashley Preston Jacqueline Rae Allison Ramsey Melissa Rendall Christie Roman Jessica Rosenbau: Beth Rother Kate Rubli Ashley Swilley Caitlin Thompson Lacey Thompso Tiffany Torregro Courtney Walker Beth Waters Amy Westerveli Crystal YBarbo Contraceptive InjGCtion corvtrol you-tMrik ae»ou± jus-t ‘■Txa^ear medroxyprogesterone acetate injectable suspension DEPO-PROVERA* Contraceptive Injection (medroxyprogesterone acetate injectable suspension, USP) This product is intended to prevent pregnancy. It does not protect against HIV infection (AIDS) and other sexually transmitted diseases. What is DEPO-PROVERA Contraceptive Injection? DEPO-PROVERA Contraceptive Injection is a form of birth control that is given as an intramuscular injection (a shot) in the buttock or upper arm once every 3 months (U weeks). To continue your contraceptive protection, you must return for your next injection promptly at the end of 3 months (\3 weeks). DEPO-PROVERA contains medroxyprogesterone acetate, a chemical similar to (out not the same as) the natural hormone progesterone, which is produced by your ovaries during the second half of your menstrual cycle. DEPO-PROVERA acts by preventing your egg cells from ripening. If an egg is not released from the ovaries during vour menstrual cycle, it cannot become fertilized by sperm and result in pregnancy. DEPO-PROVERA also causes changes_in_thejining of your uterus that make it less likely for pregnancy to occur. also causes changes in the lining ot your uterus that make it less likely t How effective is DEPO-PROVERA Contraceptive Injection?. The efficacy of DEPO-PROVERA Contraceptive Injection depends on following the recommended dosage schedule exactly (see "How often do I get my shot of DEPO-PROVERA Contraceptive Injection?"). To make sure you are not pregnant when you first get ONLY during DEPO-PROVERA Contraceptive Injection, your first injection must be given ONLY during the first 5 days of a normal menstrual period; ONLY witnin the first 5 days after childbirth if not breast-feeding; and, if exclusively breast-feeding ONLY at the sixth week after childbirth. It is a long-term iniectable contraceptive when administered at 3-month (13-week) intervals. DEPO-PROVERA Contraceptive Injection is over 99% effective, making it one of the most reliable • if you have had cancer of the breast • if you have had a stroke • if you have or have had blood clots (phlebitis) in your legs • if you have problems with your liver or liver disease • if you are allergic to DEPO-PROVERA (medroxyprogesterone acetate or any of its other ingredients). What other things should I consider before using DEPO-PROVERA Contraceptive Injection? You will have a physical examination before your doctor prescribes DEPO-PROVERA. It is important to tell your health-care provider if you have any of the following: • a family history of breast cancer • an abnormal mammogram (breast x-ray), fibrocystic breast disease, breast nodules or lumps, or bleeding from your nipples • kidney disease • irregular or scanty menstrual periods • high blood pressure • migraine headaches • asthma • epilepsy (convulsions or seizures) • diabetes or a family history of diabetes • a history of depression • if you are taking any prescription or over-the-counter medications This product is intended to prevent pregnancy. It does not protect against transmission of HIV (AIDS) and other sexually transmitted diseases such as chlamydia, genital herpes, genital warts, gonorrhea, hepatitis B, and syphilis. 6.Other Risks Women who use hormone-based contraceptives may have an increased risk of Wood clots or stroke. Also, if a contraceptive method fails, there is a possibility that the fertilized egg will begin to develop outside of the uterus (ectopic pregnancy). While these events are rare, you should tell your health-care provider if you have any of the problems listed in the next section. What symptoms may signal problems while using DEPO-PROVERA Contraceptive Injection? Call your health-care provider immediately if any of these problems occur following an injection of DEPO-PROVERA: • sharp chest pain, coughing up of blood, or sudden shortness of breath (indicating a possible clot in the lung) • sudden severe headache or vomiting, dizziness or fainting problems with your eyesight or speech, weakness, or numbness in an arm or leg (indicating a possible stroke) • severe pain or swelling in the calf (indicating a possible clot in the leg) • unusually heavy vaginal bleeding • severe pain or tenderness in the lower abdominal area • persistent pain, pus, or bleeding at the injection site What are the possible side effects of DEPO-PROVERA Contraceptive Injection? I.Weight Gain You may experience a weight gam while you are using DEPO-PROVERA. About two thirds of the women who used DEPO-PROVERA in clinical tnals reported a weight gam of about 5 pounds during the first year of use. You may continue to gain weight after the first year. Women in one ‘ ^"^D-PROVERA for 2 years gained an average total of 8.1 pounds over , per year. Women who continued for 4 years gained an large study who used DEPO- those 2 years, or approximately 4 pounds pi , , « average total of 13.8 pounds over those 4 years, or approximately 3.5 pounds per year. Women njectio methods of birth control available. This means that the average annual pregnancy rate is less than one for every 100 women who use DEPO-PROVERA. The effectiveness of most contraceptive methods depends in part on how reliably each woman uses the method. The effectiveness of DEPO-PROVERA depends only on the patient returning every 3 months (J 3 weeks) for her next injection. Your i-care provider will help you compare DEPO-PROVERA with other contraceptive methods and give you the information you need in order to decide which contraceptive method is the right cnoice for you. The following table shows the percent of women who got pregnant while using different kinds of contraceptive methods, ft gives both the lowest expected rate of pregnancy (the rate expected in women who use each method exactly as it should be used) and the typical rate of pregnancy (which includes women who became pregnant because they forgot to use their birth control or because they did not follow the directions exactly). Percent of Women Experiencing an Accidental Pregnancy In the First Year of Continuous Use Method ' Lowest Expected Typical DEPO-PROVERA 0.3 0.3 Implants (Norplant) 0.2* 02* Female sterilization 0.2 0.4 Male sterilization 0.1 0.15 Oral contraceptive (pill) 3 Combined 0.1 Progestogen only 0.5 iUD 1 3 Progestasert 2.0 CopperT 3BOA 0.8 Condom (without spermicide) 2 12 Diaphragm (with spermicide) 6 18 Cervical cap 6 18 Withdrawal 4 18 Periodic abstinence 1-9 20 Spermicide alone 3 21 Vaginal Sponge used before childbirth 6 18 used after childbirth 9 28 No method §5 85 What if I want to become pregnant after using DEPO-PROVERA Contraceptive injection? Because DEPO-PROVERA is a long-acting birth control method, it takes some time after your last injection for its effect to wear off. Based on the results from a large study done in the United States, for women who stop using DEPO-PROVERA in order to become pregnant, it is expected that about half of those who become pregnant will do so in about 10 months after their last injection; about two thirds of those who become pregnant will do so in about 12 months; about 83% of those who become pregnant will do so in about 15 months; and about 93% of those who become pregnant will do so in about 18 months after their last injection. The length of time you use DEPO-PROVERA has no effect on how longrt takes you to become pregnant after you stop using it What are the risks of using DEPO-PROVERA Contraceptive Injection? / .Irregular Menstrual Bleeding The side effect reported most frequently by women who use DEPO-PROVERA for contraception is a change in their normal menstrual cycle. During the first year of using DEPO-PROVERA, you might have one or more of the following changes: irregular or unpredictable bleeding or spotting, an increase or decrease in menstrual bleeding, or no bleeding at all. Unusually heavy or continuous bleeding, however, is not a usual effect of DEPO-PROVERA; and if this happens, you should see your health-care provider right away. With continued use of DEPO-PROVERA bleeding usually decreases, and many women stop having periods completely. In clinical studies of DEPO-PROVERA, 55% of the women studied reported no menstrual. bleeding (amenorrhea) after I year of use, and 68% of the women studied reported no menstrual bleeding after 2 years of use. The reason that your periods stop is because DEPO-PROVERA causes a resting state in your ovaries. When your ovaries do not release an egg monthly, the regular monthly growth of the lining of your uterus does not occur and, therefore, the bleeding that comes with your normal menstruation does not take place. When you stop using DEPO-PROVERA your menstrual period will usually, in time, return to its normal cycle. 2. Bone Mineral Chan^ i es Use of DEPO-PROvERA may be associated with a decrease in the amount of mineral stored in vour bones. This could increase your risk of developing bone fractures. The rate of bone mineral loss is greatest in the early years of DEPO-PROVEFIA use, but after that, it begins to resemble the normal rate of age-related bone mineral loss. 3. Cancer Studies of women who have used different forms of contraception found that women who used DEPO-PROVERA for contraception had no increased overall risk of developing cancer of the breast ovary, uterus, cervix, or liver. However women under 35 years of age whose first exposure to DEPO-PROVERA was within the previous 4 to 5 years may have a slightly increased nsk of should discuss this with your health-care provider. who continued for & years gained an average total of 16.5 pounds over those 6 years, or approximately 2.75 pounds per year. l.Olher Side Effects In a clinical study of over 3,900 women who used DEPO-PROVERA for up to 7 years, some women reported the following effects that may or may not have been related to their use of DEPO-PROVERA: Irregular menstrual bleeding, amenorrhea, headache, nervousness, abdominal cramps, dizziness, weakness or fatigue, decreased sexual desire, leg cramps, nausea, vaginal discharge or irritation, breast swelling and tenderness, bloating, swelling of the hands or feet backache, depression, insomnia, acne, pelvic pain, no hair growth or excessive hair loss, rash, hot flashes, and |oint pain. Other problems were reported by very few of the women in the clinical trials, but some of these could be serious. These include convulsions, jaundice, urinary tract infections, allergic reactions, fainting, paralysis, osteoporosis, lack of return to fertility, deep vein thrombosis, pulmonary embolus, breast cancer, or cervical cancer. If these or any other problems occur dunng your use of DEPO-PROVERA. discuss them with your health-care provider. Should any precautions be followed during use of DEPO-PROVERA Contraceptive injection? I .Missed Periods During the time you are using DEPO-PROVERA for contraception, you mav skip a period, or your penods may stop completely If you have been receiving your DEPO-PROVERA injections regularly every 3 months (13 weeks), then you are probably not pregnant However if you think that you may be pregnant see your health-care provider 2laboratory Test Interactions If you are scheduled for any laboratory tests, tell your health-care provider that you are using DEPO-PROVERA for contraception. Certain blood tests are affected by hormones such as DEPO-PROVERA. 3. Dr up Interactions Cytadren (aminoglutethimide) is an anticancer drug that may significantly decrease the effectiveness of DEPO-PROVERA if the two drugs are given during the same time. developing breast cancer similar to that seen with oral contraceptives. You s your health-! 4.Unexpected Pregnancy D-PROVERA nectiveness of DEPO-PROVE 4,Nursing Mothers Although DEPO-PROVERA can be passed to the nursing infant in the breast milk, no harmful effects nave been found in these children. DEPO-PROVERA does not prevent the breasts from producing milk, so it can be used by nursing mothers. However to minimize the amount of DEPO-PROVERA that is passed to tne infant in the first weeks after birth, you should wait until 6 weeks after childbirth before you start using DEPO-PROVERA for contraception. How often do I get my shot of DEPO-PROVERA Contraceptive Injection? The recommended dose of DEPO-PROVERA is 150 mg every 3 months (13 weeks) given in a single intramuscular injection in the buttock or upper arm. To make sure that you are not pregnant at the time of the first injection, it is essential that the injection be given ONLY during the first 5 days of a normal menstrual period. If used following the delivery of a child, the first injection of Ml 1 " rt-fec " Source.' Trussell et al. Obstet Gynecol. 1990;76:558-567. •From Norplant* package insert. Who should not use DEPO-PROVERA Contraceptive Injection? Not all women should use DEPO-PROVERA You should not use DEPO-PROVERA if you have any of the following conditions: • if you think you might be pregnant • if you have any vaginal bleeding without a known reason Because DEPO-PROVERA is such an effective contraceptive method, the risk of accidental pregnancy for women who get their shots regularly (every 3 months [13 weeks]) is very low. While there have been reports of an increased risk of low birth weight and neonatal infant death or other health problems in infants conceived close to the time of injection, such pregnancies uncommon. If you think you may have become pregnant while using DEPO-PROVERA contraception, see your health-care provider as soon as possible. S.AIIergic Reactions Some women using DEPO-PROVERA Contraceptive Injection have reported severe and potentially life-threatening allergic reactions known as anaphylaxis and anaphylactoid reactions. Symptoms include the sudden onset of hives or swelling and itching of the skin, breathing difficulties, and a drop in blood pressure. DEPO-PROVERA MUST be given within 5 days after childbirth if you are not breast-feeding or 6 weeks after childbirth if you are exclusively breast-feeding. If you wait longer than 3 months (13 weeks) between injections, or longer than 6 weeks after delivery, your health-care provider should determine that you are not pregnant before giving you your injection of DEPO-PROVERA. for Rx only Pharmacia & Upjohn Company Ml 49001, USA Kalamazoo, Ml 49001 Pharmacia & Upjohn By John ( THE AS SOCI Al ATLANTIC C Miss Vermont Neither does Dakota, Miss Moi New Mexico. In the Miss Am it’s usually women states or populous i tate-level compe stiffest — who triui Through 82 yi America contests, 21 states that hav< representative wii Experts say it’s a c factors, including pageant experienct f competition she getting to Atlantic Those who groi requirements to lift the “Libya has accepted rap bilily.” Jones Parry told the: cil on Tuesday. “Libya base where pageants at to pay a substantial sum of; get involved earlie pensation to the relatives«: more once they do who were murdered. .And. has agreed to cooperate further Lockerbie inv Down in the Si remendous beaut) ure,” said fonner | and has renounced tenomr sion pnxiucer An; The Lockerbie families * J author of “Miss p.iul S4 million each whet i Dream Lives On. sanctions against Libya are "It has to do w If the United States i of being pretty and own sanctions against Libyt| families will receive ano million and if Libya is n from the U.S. Department’s list of sponsoring terrorism, get an additional $2 millioi winning pageant: states that have hu; child pageants. It’s ness and it promote coat women are bom the) from infancy,” sai former member of television productii There are other _ Pageant organ Double You Jeep roots in the Employme' steady sponsorship Opportunity 0 f success in Atla * V-frA Toro \iro11 SiimJn Abro*) liLd» f 0 fare wel1 when ' or call Toll Fre«: l^66W* Got Renter Insurance! FREE QUOTi 979-693-1681 reach Atlantic City “The ones tha )he ones with goo it the state level, Strong executive b< |the.pageant like said Lois Elaine liss Washington J ageant board m ijsee this in Texas, south Carolina. T1 /ith a profile of p; Bruce Boyd i Vote Continued from Conversations j on Leadership in Public Life News Makers ! The group’s 2 New? Breaker P ppeared lin,ed 10 cttivci ative action agains f33-member faci [Earlier Tuesday, 'ho spoke on monymity, said )elieved they had >ass the no-confid Chuck Weaver Immediate past c Jhe did not know w Jsenate would take. The meeting lounting pressui Keynote speakers | circles for Slo£ Dr. Robert M, Gates, Preside [ leaded the wo Texas A&M University >-Baptist universi Wayne Slater, Austin Burti | y ear s, to step dov Chief, Dallas MorningNfr \ * n recer >t dt j Baylor's 36 rege Panelists ( former regent cl State Rep. Fred Brown, (Jcalled for Sloan’s DistricI 14 Cindy Lawson, Saturday, Sept. 13,1 10 a.m. to 2 p.m. Texas A&M Universit) Memorial Student Cents: Room 292 Executive Director, University Relfr j Dave McNeely, political columnist, Austin American-Statesmm Fiie-sharii Continued frorr Gary Borders, , , , publisher, Lufkin Daily Nam j bandwidth and 11( Mike Sims, Class of’87. j * be swapping former student body presided i music industry-a Brooke Rollins, Class oft! decline in sales former student body presideni | RIAA Loren Steffy, Class of'87; Marti said he iormer Battalion editor mm . , Scot Walker, Class of*. ; Mownloading mu: former editor in chief , behind the ISSUe. pKvay to get to the Online registration http://battalion.tamu.edu Deadline: 5 p.m. Wednesdai • Registration limited to 125 student lei and 75 student journalists • TWo participants per student orflantf • Lunch provided Computing & ■set to warn studer ifthat file swa i http://itim.tamu.e Sponsored by the Division of Student Media Office of University Relations Department of Student Life If You Have Something To- Remember: ■; Classifieds Can Dolt ; Call 845-0569 ; The Battalion j Fall 20 8 Game Se; Games are : For more info